Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Mini Review on Cariprazine: A Promising Antipsychotic Agent

Author(s): Ashish Patel*, Arya Patel, Darshini Patel, Krina Patel and Tushar Bambharoliya

Volume 22, Issue 2, 2023

Published on: 22 April, 2022

Page: [226 - 236] Pages: 11

DOI: 10.2174/1871527321666220324121935

Price: $65

Abstract

Cariprazine is a piperazine derivative approved by the USFDA in 2015 as a novel atypical antipsychotic drug (APD) to treat adults with schizophrenia and bipolar manic or mixed episodes in adults. However, due to the partial agonist action on dopamine D2, D3 receptors, and serotonin 5-HT1A receptors as well as the antagonist effect on 5-HT2A, 5-HT2B, and H1 receptors, cariprazine differs pharmacologically from other APDs, both typical and atypical. Moreover, cariprazine also has a unique pharmacokinetic profile due to the formation of two clinically significant metabolites: desmethyl-cariprazine (DCAR) and desmethyl-cariprazine (DDCAR). They are eliminated by CYP3A4 and also, to a lesser extent, by CYP2D6. Here, we also review the effectiveness, safety, as well as current clinical update of cariprazine in bipolar I disorder associated with/without mania and schizophrenia through randomized and post-hoc analysis. The potential benefits of cariprazine as a promising therapeutic alternative in addressing major clinical requirements for better therapy of such severe neuropsychiatric conditions were demonstrated in this summarized review study.

Keywords: Cariprazine, Dopamine(D2/D3) Receptor, DCAR, DDCAR, Schizophrenia, Bipolar I disorder.

« Previous Next »
Graphical Abstract

[1]
American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR. (4th ed.), Arlington, Virginia 2000.
[2]
Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: Heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009; 10(12): 1917-28.
[http://dx.doi.org/10.1517/14656560903061309] [PMID: 19558339]
[3]
Mazza M, Marano G, Traversi G, Carocci V, Romano B, Janiri L. Cariprazine in bipolar depression and mania: State of the art. CNS Neurol Disord Drug Targets 2018; 17(10): 723-7.
[http://dx.doi.org/10.2174/1871527317666180828120256] [PMID: 30152291]
[4]
Amodeo G, Fagiolini A, Sachs G, Erfurth A. Older and newer strategies for the pharmacological management of agitation in patients with bipolar disorder or schizophrenia. CNS Neurol Disord Drug Targets 2017; 16(8): 885-90.
[PMID: 28933260]
[5]
Vazquez GH, Camino S, Tondo L, Baldessarini RJ. Potential novel treatments for bipolar depression: Ketamine, fatty acids, anti-inflammatory agents, and probiotics. CNS Neurol Disord Drug Targets 2017; 16(8): 858-69.
[PMID: 28758582]
[6]
Scarff JR. Cariprazine for schizophrenia and bipolar disorder. Innov Clin Neurosci 2016; 13(9-10): 49-52.
[PMID: 27975000]
[7]
Gründer G. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr Opin Investig Drugs 2010; 11(7): 823-32.
[PMID: 20571978]
[8]
Citrome L. Cariprazine: Chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol 2013; 9(2): 193-206.
[http://dx.doi.org/10.1517/17425255.2013.759211] [PMID: 23320989]
[9]
Gingrich JA, Caron MG. Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 1993; 16(1): 299-321.
[http://dx.doi.org/10.1146/annurev.ne.16.030193.001503] [PMID: 8460895]
[10]
Sibley DR, Monsma FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992; 13(2): 61-9.
[http://dx.doi.org/10.1016/0165-6147(92)90025-2] [PMID: 1561715]
[11]
Beaulieu JM, Gainetdinov RR, Caron MG. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 2007; 28(4): 166-72.
[http://dx.doi.org/10.1016/j.tips.2007.02.006] [PMID: 17349698]
[12]
Earley W, Guo H, Daniel D, et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophr Res 2019; 204: 282-8.
[http://dx.doi.org/10.1016/j.schres.2018.08.020] [PMID: 30172595]
[13]
Allergan and gedeon richter receive U.S.. FDA approval for expanded use of VRAYLAR® (cariprazine) in the treatment of bipolar depression Dublin and Budapest, Allergan. Available from: http://www.prnewswire.com/news-releases/allergan-and-gedeon-richter-receive-us-fdaapproval-for-expanded-use-of-vraylar-caripra- zine-in-the-treatment-of-bipolar-depression 300857106.html (Accessed October 21, 2020).
[14]
Calabrese F, Tarazi FI, Racagni G, Riva MA. The role of dopamine D3 receptors in the mechanism of action of cariprazine. CNS Spectr 2020; 25(3): 343-51.
[http://dx.doi.org/10.1017/S109285291900083X] [PMID: 31010452]
[15]
De Berardis D, Orsolini L, Iasevoli F, et al. The novel antipsychotic cariprazine (RGH-188): State-of-the-art in the treatment of psychiatric disorders. Curr Pharm Des 2016; 22(33): 5144-62.
[http://dx.doi.org/10.2174/1381612822666160701084447] [PMID: 27396597]
[16]
Agai-Csongor E, Domány G, Nógrádi K, et al. Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg Med Chem Lett 2012; 22(10): 3437-40.
[http://dx.doi.org/10.1016/j.bmcl.2012.03.104] [PMID: 22537450]
[17]
Periclou A, Willavize S, Jaworowicz D, et al. Relationship between plasma concentrations and clinical effects of cariprazine in patients with schizophrenia or bipolar mania. Clin Transl Sci 2020; 13(2): 362-71.
[http://dx.doi.org/10.1111/cts.12720] [PMID: 31664765]
[18]
Mathe TB, Hegedus L, Czibula L, Juhasz B, Nagyne BJ, Markos D. Process for the preparation of trans 4-amino-cyclohexyl acetic acid ethyl ester HCl. U.S. Patent 8,802,888, 2010.
[19]
Ágainé CE, Czibula L, Sebök F, Domany G, Greiner I. Novel piperazine salts as d3/d2 antagonists. W.O. Patent 2008/139235, 2008.
[20]
Flick AC, Ding HX, Leverett CA, et al. Synthetic approaches to the new drugs approved during 2015. J Med Chem 2017; 60(15): 6480-515.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00010] [PMID: 28421763]
[21]
Deák K, Takács-Novák K, Kapás M, Vastag M, Tihanyi K, Noszál B. Physico-chemical characterization of a novel group of dopamine D(3)/D(2) receptor ligands, potential atypical antipsychotic agents. J Pharm Biomed Anal 2008; 48(3): 678-84.
[http://dx.doi.org/10.1016/j.jpba.2008.06.021] [PMID: 18692339]
[22]
Gyertyán I, Kiss B, Sághy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int 2011; 59(6): 925-35.
[http://dx.doi.org/10.1016/j.neuint.2011.07.002] [PMID: 21767587]
[23]
Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: An evidence-based medicine approach. CNS Drugs 2013; 27(11): 879-911.
[http://dx.doi.org/10.1007/s40263-013-0105-7] [PMID: 24062193]
[24]
Mauri MC, Paletta S, Maffini M, et al. Clinical pharmacology of atypical antipsychotics: An update. EXCLI J 2014; 13: 1163-91.
[PMID: 26417330]
[25]
Tóth M, Varrone A, Steiger C, et al. Brain uptake and distribution of the dopamine D3/D2 receptor partial agonist [11 C]cariprazine: An in vivo positron emission tomography study in nonhuman primates. Synapse 2013; 67(5): 258-64.
[http://dx.doi.org/10.1002/syn.21631] [PMID: 23238770]
[26]
McCormack PL. Cariprazine: First global approval. Drugs 2015; 75(17): 2035-43.
[http://dx.doi.org/10.1007/s40265-015-0494-7] [PMID: 26510944]
[27]
Kirschner N, Gemesi LI, Vastag M. In vitro metabolism of RGH-188. Drug Metab Rev 2008; 40: 128-9.
[28]
Mészáros GP, Agai-Csongor E, Kapás M. Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine. J Pharm Biomed Anal 2008; 48(2): 388-97.
[http://dx.doi.org/10.1016/j.jpba.2007.12.016] [PMID: 18242914]
[29]
Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: In vitro and neurochemical profile. J Pharmacol Exp Ther 2010; 333(1): 328-40.
[http://dx.doi.org/10.1124/jpet.109.160432] [PMID: 20093397]
[30]
Meszaros GP, Kapas M, Borsos M. Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic candidate. Eur Psychiatry 2008; 23: S163.
[http://dx.doi.org/10.1016/j.eurpsy.2008.01.946]
[31]
Stahl SM. Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications. (4th ed.), Cambridge: Cambridge University Press 2013.
[32]
Misiak B. Bieńkowski P, Samochowiec J. Cariprazine - a novel antipsychotic drug and its place in the treatment of schizophrenia. Psychiatr Pol 2018; 52(6): 971-81.
[http://dx.doi.org/10.12740/PP/OnlineFirst/80710] [PMID: 30659560]
[33]
Caccia S. Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opin Drug Metab Toxicol 2011; 7(7): 829-46.
[http://dx.doi.org/10.1517/17425255.2011.575061] [PMID: 21476873]
[34]
Citrome L. The ABC’s of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: The 15-min challenge to sort these agents out. Int J Clin Pract 2015; 69(11): 1211-20.
[http://dx.doi.org/10.1111/ijcp.12752] [PMID: 26477545]
[35]
Stahl SM. Stahl’s essential psychopharmacology: The prescribers guide. (5th ed.), New York: Cambridge University Press 2014.
[36]
Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: Results From an international, phase III clinical trial. J Clin Psychopharmacol 2015; 35(4): 367-73.
[http://dx.doi.org/10.1097/JCP.0000000000000346] [PMID: 26075487]
[37]
Stahl SM. Mechanism of action of cariprazine. CNS Spectr 2016; 21(2): 123-7.
[http://dx.doi.org/10.1017/S1092852916000043] [PMID: 26956157]
[38]
Corponi F, Fabbri C, Bitter I, et al. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol 2019; 29(9): 971-85.
[http://dx.doi.org/10.1016/j.euroneuro.2019.06.008] [PMID: 31255396]
[39]
Mucci F, Della Vecchia A, Baroni S, Marazziti D. Cariprazine as a therapeutic option for schizophrenia: A drug evaluation. Expert Opin Pharmacother 2021; 22(4): 415-26.
[http://dx.doi.org/10.1080/14656566.2020.1845315] [PMID: 33126812]
[40]
Citrome L. Cariprazine for acute and maintenance treatment of adults with schizophrenia: An evidence-based review and place in therapy. Neuropsychiatr Dis Treat 2018; 14: 2563-77.
[http://dx.doi.org/10.2147/NDT.S159704] [PMID: 30323605]
[41]
Berardis D, Rapini G, Olivieri L, et al. Cariprazine add-on in inadequate clozapine response: A report on two cases. Clin Psychopharmacol Neurosci 2021; 19(1): 174-8.
[http://dx.doi.org/10.9758/cpn.2021.19.1.174] [PMID: 33508803]
[42]
Bolonna AA, Kerwin RW. Partial agonism and schizophrenia. Br J Psychiatry 2005; 186(1): 7-10.
[http://dx.doi.org/10.1192/bjp.186.1.7] [PMID: 15630117]
[43]
Duric V, Banasr M, Franklin T, et al. Cariprazine exhibits anxiolytic and dopamine D3 receptor dependent antidepressant effects in the chronic stress model. Int J Neuropsychopharmacol 2017; 20(10): 788-96.
[http://dx.doi.org/10.1093/ijnp/pyx038] [PMID: 28531264]
[44]
Auclair AL, Cathala A, Sarrazin F, et al. The central serotonin 2B receptor: A new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J Neurochem 2010; 114(5): 1323-32.
[PMID: 20534001]
[45]
Meyer JM, Loebel AD, Schweizer E. Lurasidone: A new drug in development for schizophrenia. Expert Opin Investig Drugs 2009; 18(11): 1715-26.
[http://dx.doi.org/10.1517/13543780903286388] [PMID: 19780705]
[46]
Seneca N, Finnema SJ, Laszlovszky I, et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl) 2011; 218(3): 579-87.
[http://dx.doi.org/10.1007/s00213-011-2343-z] [PMID: 21625907]
[47]
Laszlovsky I, Nemeth G, Meszaros GP, et al. Dopamine D2/D3 receptor occupancy of RGH-188, a D3/D2, antagonist/partial agonist antipsychotic, in healthy volunteers. Eur Neuropsychopharmacol 2007; 17(4): S455.
[http://dx.doi.org/10.1016/S0924-977X(07)70690-9]
[48]
Roberts RJ, Findlay LJ, El-Mallakh PL, El-Mallakh RS. Update on schizophrenia and bipolar disorder: Focus on cariprazine. Neuropsychiatr Dis Treat 2016; 12: 1837-42.
[http://dx.doi.org/10.2147/NDT.S97616] [PMID: 27524901]
[49]
Girgis RR, Slifstein M, D’Souza D, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl) 2016; 233(19-20): 3503-12.
[http://dx.doi.org/10.1007/s00213-016-4382-y] [PMID: 27525990]
[50]
Arakawa R, Ito H, Takano A, et al. Dopamine D2 receptor occupancy by perospirone: A positron emission tomography study in patients with schizophrenia and healthy subjects. Psychopharmacology (Berl) 2010; 209(4): 285-90.
[http://dx.doi.org/10.1007/s00213-010-1783-1] [PMID: 20349050]
[51]
Potkin S, Keator D, Mukherjee J, et al. Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients. Eur Neuropsychopharmacol 2009; 19(3): S316.
[http://dx.doi.org/10.1016/S0924-977X(09)70472-9]
[52]
Papp M, Gruca P. Lasoń-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol 2014; 25(5-6): 567-74.
[http://dx.doi.org/10.1097/FBP.0000000000000070] [PMID: 25083572]
[53]
Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl) 2013; 226(1): 91-100.
[http://dx.doi.org/10.1007/s00213-012-2896-5] [PMID: 23079899]
[54]
Stahl SM. Drugs for psychosis and mood: Unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr 2017; 22(5): 375-84.
[http://dx.doi.org/10.1017/S1092852917000608] [PMID: 28965530]
[55]
U.S food and drug administration cariprazine drug approval and database. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig2s000TOC.cfm (Accessed Nov 3, 2020).
[56]
Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: A phase II trial. Bipolar Disord 2015; 17(1): 63-75.
[http://dx.doi.org/10.1111/bdi.12238] [PMID: 25056368]
[57]
Durgam S, Earley W, Lipschitz A, et al. An 8-week randomized, double-blind, placebocontrolled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry 2016; 173(3): 271-81.
[http://dx.doi.org/10.1176/appi.ajp.2015.15020164] [PMID: 26541814]
[58]
McIntyre RS, Suppes T, Earley W, Patel M, Stahl SM. Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: Post hoc analysis of 3 randomized, placebo-controlled studies. CNS Spectr 2020; 25(4): 502-10.
[http://dx.doi.org/10.1017/S1092852919001287] [PMID: 31576791]
[59]
Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. Schizophr Res 2014; 152(2-3): 450-7.
[http://dx.doi.org/10.1016/j.schres.2013.11.041] [PMID: 24412468]
[60]
Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: A pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol 2017; 32(6): 319-28.
[http://dx.doi.org/10.1097/YIC.0000000000000187] [PMID: 28692485]
[61]
Nasrallah HA, Earley W, Cutler AJ, et al. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: A post hoc pooled analysis. BMC Psychiatry 2017; 17(1): 305-18.
[http://dx.doi.org/10.1186/s12888-017-1459-z] [PMID: 28836957]
[62]
Calabrese JR, Keck PE Jr, Starace A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: A double-blind, placebo-controlled study. J Clin Psychiatry 2015; 76(3): 284-92.
[http://dx.doi.org/10.4088/JCP.14m09081] [PMID: 25562205]
[63]
Sachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, phase III trial. J Affect Disord 2015; 174: 296-302.
[http://dx.doi.org/10.1016/j.jad.2014.11.018] [PMID: 25532076]
[64]
Earley W, Burgess MV, Rekeda L, et al. Cariprazine treatment of bipolar depression: A randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry 2019; 176(6): 439-48.
[http://dx.doi.org/10.1176/appi.ajp.2018.18070824] [PMID: 30845817]
[65]
Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry 2015; 76(12): e1574-82.
[http://dx.doi.org/10.4088/JCP.15m09997] [PMID: 26717533]
[66]
Durgam S, Earley W, Li R, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr Res 2016; 176(2-3): 264-71.
[http://dx.doi.org/10.1016/j.schres.2016.06.030] [PMID: 27427558]
[67]
Ketter TA, Sachs GS, Durgam S, et al. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study. J Affect Disord 2018; 225: 350-6.
[http://dx.doi.org/10.1016/j.jad.2017.08.040] [PMID: 28843918]
[68]
Cutler AJ, Durgam S, Wang Y, et al. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: Results from a 1-year open-label study. CNS Spectr 2018; 23(1): 39-50.
[http://dx.doi.org/10.1017/S1092852917000220] [PMID: 28478771]
[69]
McIntyre RS, Masand PS, Earley W, Patel M. Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials. J Affect Disord 2019; 257: 600-6.
[http://dx.doi.org/10.1016/j.jad.2019.07.020] [PMID: 31344528]
[70]
Durgam S, Litman RE, Papadakis K, Li D, Németh G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: A proof-of-concept trial. Int Clin Psychopharmacol 2016; 31(2): 61-8.
[http://dx.doi.org/10.1097/YIC.0000000000000110] [PMID: 26655732]
[71]
Durgam S, Earley W, Lu K, et al. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis. Int J Clin Pract 2017; 71(12): 1-11.
[http://dx.doi.org/10.1111/ijcp.13037] [PMID: 29119668]
[72]
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2): 261-76.
[http://dx.doi.org/10.1093/schbul/13.2.261] [PMID: 3616518]
[73]
Busner J, Targum SD. The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry (Edgmont) 2007; 4(7): 28-37.
[PMID: 20526405]
[74]
Stahl SM, Laredo S, Morrissette DA. Cariprazine as a treatment across the bipolar I spectrum from depression to mania: Mechanism of action and review of clinical data. Ther Adv Psychopharmacol 2020; 10: 2045125320905752.
[http://dx.doi.org/10.1177/2045125320905752] [PMID: 32110377]
[75]
Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I. The effect of cariprazine on hostility associated with schizophrenia: Post hoc analyses from 3 randomized controlled trials. J Clin Psychiatry 2016; 77(1): 109-15.
[http://dx.doi.org/10.4088/JCP.15m10192] [PMID: 26845266]
[76]
Laszlovszky I, Barabássy Á, Németh G. Cariprazine, A broad-spectrum antipsychotic for the treatment of schizophrenia: Pharmacology, efficacy, and safety. Adv Ther 2021; 38(7): 3652-73.
[http://dx.doi.org/10.1007/s12325-021-01797-5] [PMID: 34091867]
[77]
Earley WR, Burgess MV, Khan B, et al. Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study. Bipolar Disord 2020; 22(4): 372-84.
[http://dx.doi.org/10.1111/bdi.12852] [PMID: 31628698]
[78]
Durgam S, Greenberg WM, Li D, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: Results from a 48-week, single-arm, open-label extension study. Psychopharmacology (Berl) 2017; 234(2): 199-209.
[http://dx.doi.org/10.1007/s00213-016-4450-3] [PMID: 27807604]
[79]
Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162(3): 441-9.
[http://dx.doi.org/10.1176/appi.ajp.162.3.441] [PMID: 15741458]
[80]
Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: Validity, frequency, predictors, and patients’ perspective 5 years later. Dialogues Clin Neurosci 2010; 12(3): 393-407.
[http://dx.doi.org/10.31887/DCNS.2010.12.3/mlambert] [PMID: 20954433]

Rights & Permissions Print Cite
Article Metrics
34
2
© 2024 Bentham Science Publishers | Privacy Policy